259 T2DM patients with microalbuminuria eUACR >30 irrespective of their A1c, on standard glucose lowering, lipid lowering and ARB (telmisartan TM or valsartan Vs as first line BP lowering therapy until optimal dose was achieved, were followed-up for 2 years. Renal (Cr, eGFR, UACR) and CV (BP, BMI, Lipid profile, hs-CRP) parameters were assessed every 6 months. NT-ProBNP was measured at the end of 2 years. Patients with history of major surgery, coronary intervention, IHD or hospitalization in last 1 year, eGFR <45, hyperkalemia >5.3 were excluded Data was analyzed using PSPP version 1.0.1 and represented as Mean (SD) and paired-t test was used, p-value of 0.05 was considered to be significant.

Results: 42.1% used TM and 57.9% used Vs. Average dose of TM 66.76mg (±52.63) and Vs 165.33 (±89.94) Baseline characteristics: 259 patients (females 45.6%, male 54.4%), mean age 61.22 years (±9.50); weight 78.91kg (±15.78), BMI 30.63 (5.81±), DOD 12.9 years (7.52±), SBP 137.09mm (±20.60), DBP 77.54 (±11.31). There was a significant mean reduction observed in HbA1c 1.21% (95% CI 1.02-1.39, p-<0.001), SBP 3.37mm (95% CI 0.66-6.08, p-0.015), TC 14.13mg% (95% CI 8.43-19.83, p <0.001), LDL 10.64mg% (95% CI 5.87-15.41, p <0.001), TG 19.52mg% (95% CI 11.50-27.55, p<0.001), non-HDL 25.31mg% (95% CI 18.95-31.66, p<0.001), Chol remnant 8.25mg% (95% CI 5.27-11.22, p <0.001), UACR 147.5mg% (95% CI 61.27-233.79, p 0.001). There was no significant change seen in weight, BMI, DBP, HDL, Cr, eGFR, potassium. The NT-ProBNP was 166.30 pg/ml (±242.72) remained elevated after 2 years.

Conclusion: Despite optimal use of ARB and reduction in renal (UACR, maintenance of renal function) and CV risk factors there remains a significant risk for future CV mortality as suggested by elevated NT-ProBNP in T2DM with microalbuminuria.


V. Gupta: None. V. Teli: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.